The high-dose formulation of the Alzheimer’s treatment ‘Ebixa’ has landed at general hospitals in Korea.

According to industry sources, Lundbeck Korea’s ‘Ebixa (memantine) tablet 20mg’ passed the drug committees of medical institutions in Korea, including Seoul National University Hospital, Seoul Asan Medical Center, Sinchon Severance Hospital, and Seoul National University Bundang Hospital. The drug has stably established a prescription environment in Korea since its launch in August last year.

Ebixa is an NMDA receptor antagonist approved for the treatment of moderate-to-severe Alzheimer’s disease. It blocks glutamate, a neurotransmitter involved in learning and memory, to preve